Bio Essence Corp Cash Flow Statement
BIOE|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
$2M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Bio Essence Corp generated $2M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 8/9 criteria passed
- Negative shareholders equity: Liabilities exceed assets
- Cash-backed earnings: Operating cash flow exceeds net income
- Profit margin: 47.2% of revenue retained as profit
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | $896.2K | -$1.3M | -$971.9K | -$809.7K | -$647.6K |
| Depreciation & Amortization | $235 | $911 | $4.8K | $14.5K | $35.8K |
| Operating Cash Flow | $1.6M | $623.9K | -$1.0M | -$703.2K | -$1.3M |
| Capital Expenditures | - | - | $3.6K | $3.7K | $119.5K |
| Free Cash Flow | - | - | -$1.0M | -$707.0K | -$1.4M |
| FCF Margin | - | - | -186.6% | -113.7% | -159.2% |